Nuwellis (Nasdaq:NUWE) announced today that it entered into a supply and collaboration agreement with DaVita (NYSE:DVA).
The agreement enables Nuwellis — formerly CHF Solutions — to pilot its Aquadex ultrafiltration therapy within selected U.S. markets. Aquadex, which removes excess fluid from patients suffering from hypervolemia (fluid overload), treats congestive heart failure and related conditions.
DaVita offers extracorporeal therapies like continuous renal replacement therapy and apheresis. The company recently launched a joint dialysis venture with Medtronic called “Mozarc Medical.”
Pairing Aquadex with DaVita’s care team could expand access to ultrafiltration therapy, Nuwellis said. The company also aims for this deal to reduce related healthcare costs for providers and payers.
“We are honored that DaVita is collaborating with Nuwellis to pilot a services model alongside Aquadex,” said Nestor Jaramillo, Jr., president and…